REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for patients when CAR-T fails: immunotherapy trial targets stubborn blood cancers
Disease control OngoingThis study is testing whether the immunotherapy drug nivolumab can help control blood cancers that have returned, stopped responding, or are still detectable after a patient has already received CAR-T cell therapy. It is for adults with specific types of lymphoma, leukemia, or mu…
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug combo tested for Tough-to-Treat blood cancers
Disease control OngoingThis early-stage study is testing the safety and best dose of a new drug, pevonedistat, when given with an existing drug, ibrutinib. It is for adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal i…
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Double-Target CAR-T cells tested in fight against tough blood cancers
Disease control OngoingThis early-stage study is testing the safety and best dose of a new type of CAR-T cell therapy designed to attack two common proteins (CD19 and CD20) found on certain blood cancer cells. The therapy involves collecting a patient's own immune cells, modifying them in a lab to reco…
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New Triple-Threat attack on blood cancer tested in patients
Disease control OngoingThis study is testing whether a combination of three drugs—acalabrutinib, umbralisib, and ublituximab—can control the growth of chronic lymphocytic leukemia (CLL). It is enrolling adults with CLL, including those whose cancer has come back after treatment and those who have never…
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Jennifer R. Brown, MD, PhD • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Double-Drug attack on blood cancer shows promise
Disease control OngoingThis study tests whether taking two oral medications together—venetoclax and ibrutinib—can better control chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It is for adults whose cancer has returned after prior treatment or who have high-risk, untreated dis…
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New dosing strategy aims to tame blood cancer with fewer side effects
Disease control OngoingThis study is testing whether giving the cancer drug duvelisib on an irregular schedule works as well as continuous dosing but with fewer severe side effects. It is for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding …
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Triple-Threat attack on blood cancer shows promise
Disease control OngoingThis study is testing a combination of three different drugs (obinutuzumab, ibrutinib, and venetoclax) to treat chronic lymphocytic leukemia (CLL). It aims to find the safest dose and see how well the combination works for patients whose cancer has returned, is resistant to treat…
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Kerry Rogers • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New strategy aims to tame dangerous virus after cancer transplant
Disease control OngoingThis study is testing a personalized plan to manage cytomegalovirus (CMV), a common and potentially serious infection, in patients who have received a donor stem cell transplant for blood cancers or disorders. The plan involves closely monitoring the virus level and the patient's…
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
Early trial tests Triple-Threat attack on stubborn blood cancers
Disease control OngoingThis early-phase study is testing a combination of three drugs—lenalidomide, ibrutinib, and rituximab—in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to other treatments. The main goals are to find t…
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC
-
New hope for patients Who've run out of options: experimental drug enters human testing
Disease control OngoingThis early-stage study is testing a new oral drug called BGB-21447 in adults with certain advanced blood cancers that have returned or stopped responding to other treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also loo…
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC
-
New 'Living Drug' trial offers hope for patients with aggressive lymphoma
Disease control OngoingThis study is testing a new type of personalized cell therapy for patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has come back or not responded to standard treatments. Doctors take a patient's own immune cells, genetically modify them to better tar…
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 05, 2026 13:59 UTC